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Background: Obesity is currently regarded as a pro-inflammatory condition during which leptin (Ob gene product)
might act as a risk factor for Cardiovascular Diseases (CVD) including Acute Myocardial Infarction (AMI). There is a
marked increase in circulating leptin concentrations and inflammatory markers such as Tumor Necrosis Factor-α
(TNF-α) in AMI patients but still the association of leptin with inflammation during AMI is not known. The present
study suggest that elevated levels of leptin might elicit the risk for CVD by signaling for the secretion of inflammatory
cytokines especially, TNF-α.
Methods: Blood samples were collected from 100 CVD subjects diagnosed for AMI immediately after their admission
to the hospital and serum leptin, insulin, glucose, lipids and inflammatory marker such as TNF-α were measured. 5 ml
random (non-fasting) blood was collected from 100 non-CVD (control) subjects and the results obtained in case of AMI
subjects were compared with that of the control subjects. The subjects under study included both men and women
belonging to the age group of 35 – 75 and they were classified based on their BMI as normal weight, overweight and
obese.
Results: Circulating levels of leptin are found to be elevated in obese control subjects and in patients with AMI
irrespective of their Body Mass Index (BMI). In addition, leptin is also found to be positively correlated to serum
triglycerides, insulin and TNF-α in AMI subjects. MANOVA analysis suggests that leptin might influence the synthesis of
insulin and TNF-α. This is the first report relating leptin to TNF-α in Chennai based population, India.
Conclusions: Hyperleptinemia might act as a risk marker for AMI. The present study suggests that at elevated levels,
leptin may favor atherosclerosis by promoting the synthesis of TNF-α and insulin. However, our report warrants further
investigation both in vitro and in vivo to determine the exact mechanism behind the pro-atherogenic role of leptin. The
observed positive correlation between leptin and BMI in both AMI and control subjects suggests that obese subjects
manifest leptin resistance and hence, they possess a greater risk for the incidence of CVD.
Keywords: Leptin, Insulin, Tumor necrosis factor-α, Obesity, Acute Myocardial Infarction, Cardiovascular DiseasesBackground
Obesity, an emerging epidemic of industrialized coun-
tries is currently proclaimed to be a pro-inflammatory
state with inflammation playing an active role in the
pathophysiology of Cardiovascular Diseases (CVD) [1,2].
But still, the key mechanisms that link elevated fat mass
with inflammation during CVD including AMI remain* Correspondence: r_malathi@hotmail.com
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unless otherwise stated.elusive. Leptin, a 16 KDa protein hormone is a novel
and very promising molecule of research that may act as
a mediator between obesity and CVD [3]. It is one of the
most important adipocytokine that modulates metabolic
processes by regulating energy intake and expenditure,
including appetite and metabolism [4]. Apart from me-
tabolism, leptin has systemic effects including regulation
of angiogenesis, wound healing, lipolysis, blood pressure
homeostasis, reproduction, hematopoiesis and immune
function [5]. Despite the weight reducing effects of leptin,
obese individuals possess unusually high concentrations ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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resistance.
Leptin signaling pathway is a complex network that reg-
ulates a cellular pathway involved in a myriad of physio-
logical and pathological scenarios. Leptin transmits signal
by binding to its receptor Ob-R, which belongs to the class
I cytokine receptor family. The long form, namely Ob-Rb
is essential in mediating most of the biological effects of
leptin and is highly expressed in the hypothalamus. It is
also found to be expressed in several cell types relevant
to CVD (eg, macrophage, endothelial cell, and smooth
muscle cells) thus providing evidence for the role of
leptin in signaling for atherogenic events [6].
Serum leptin levels are reported to be associated with
various cardiovascular risks, including stroke, chronic
heart failure [7,8], acute myocardial infarction [9], coron-
ary heart disease [10], and left cardiac hypertrophy [11]. It
is an important factor operating in the metabolic alter-
ation taking place during myocardial infarction and is a
possible risk factor [12-14]. One of the molecular mechan-
ism by which leptin promotes the onset of AMI is its abil-
ity to modulate immune response. Evidence suggests that
leptin can stimulate inflammatory response by activating
TNF-α via p38 and JNK MAPK pathway [15] and these in-
flammatory markers may be associated with the risk of re-
current myocardial infarction and death [16]. The normal
physiological effect of leptin on the regulation of TNF-α
expression seems to be suppressive, but the hyperleptine-
mic condition and leptin resistance may both contribute
to the rise of TNF-α in the adipose tissue in obesity [17].
Also, several pieces of evidence indicate that TNF-α is an
important player in the state of insulin resistance observed
during obesity which in turn contributes to several patho-
logical problems of obese patients such as hyperlipidemia,
arteriosclerosis and hypertension [18,19]. Given that both
of these cytokines are overproduced in the adipose tissue
of obese individuals and released into the circulation, they
may augment inflammatory response and could be in-
volved in the pathogenesis of the CVD during obesity.
Epidemiological studies show striking differences in
the extent and severity of CVD when people from differ-
ent populations are compared. The present study exam-
ines the relationship between obesity, leptin and AMI in
Chennai based population. The present study focuses on
the following 1. To determine the values of leptin, insu-
lin and TNF-α in AMI and control subjects of different
BMI 2. To understand the pro-atherogenic role of leptin
by analyzing its influence over the secretion of insulin,
TNF-α and triglycerides.
Methods
The relationship between leptin, insulin, biochemical
and inflammatory markers were studied in subjects with
AMI (CVD subjects) and control (non-CVD) subjects.About 100 CVD patients considered for the present
study were diagnosed for AMI and admitted to ICCU,
Stanley Medical College and Hospital, Chennai. The
study population included 79 men and 21 women be-
longing to the age group of 35 – 75 and AMI was diag-
nosed in these patients based on acute changes in ST
elevations in ECG. Detailed history was recorded from
the patients with reference to the features of chest pain,
location, radiation, aggravating and relieving factors, in-
creased autonomic activity and other clinical features. The
diagnosis of AMI was based on clinical and electrographic
evidence using the criteria recommended by WHO.
Trained nurses administered questionnaires to obtain in-
formation on each patient’s date of birth, occupation,
current cigarette smoking and alcohol use. After obtaining
a written consent, random blood samples (5 mL) were col-
lected from the AMI subjects at the time of their admis-
sion to ICCU, Stanley Medical College and Hospital,
Chennai. Blood was then allowed to clot and it was
retracted and separated by centrifugation at 3500 rpm for
10 minutes. Serum was separated using standard protocol
and stored at −80°C.
100 control (non-CVD) subjects chosen for the present
study were those who had no history of incidence of CVD.
The study population consisted of 77 men and 23 women
belonging to the age group of 35 – 75 and was devoid of
diabetes, any heart disease, thyroid disorders and arthritis.
None of the subjects were on medication known to affect
insulin action or plasma lipoprotein – lipid levels and they
were not on any inflammatory drug either before or at the
time of the study. People with the habits of smoking and
alcohol consumption and the individuals using aspirin as a
chronic medication were excluded from the study and the
subjects were under no medication for at least 3 months
before the study. Written consent was obtained from the
above subjects to participate in the present study. Trained
interviewers administered questionnaires to obtain infor-
mation on each subject’s date of birth, occupation, current
cigarette smoking and alcohol use. 5 ml of random (non-
fasting) blood samples were collected from them, serum was
separated using standard protocols and stored at −80°C.
All the subjects under study were categorized based on
BMI, as normal weight, overweight and obese. The cut off
range for BMI is as follows: normal weight - 18.5-22.99;
overweight - 23.0-27.49; obese - >27.5.
BMI was calculated using the formula – Weight (Kg)/
Height (m2). Waist to Hip ratio (WHR) was calculated as
waist circumference (in inches) divided by inch circumfer-
ence (in inches). Blood pressure was measured using mer-
cury sphygmomanometer.
Biochemical parameters
Serum parameters such as glucose was estimated using
GOD-POD method [20], triglycerides using GPO-POD-
Table 1 Values of serum leptin, insulin, TNF-α, glucose, triglycerides, cholesterol, HDL, LDL and VLDL in AMI and
control (non-CVD) subjects






















5.7 ± 3.8 2.6 ± 0.97 14.6 ± 2.3 124.6 ±
14.3








19.4 ± 3.3 13.4 ± 3.3 37.9 ± 5.2 152.3 ±
18.6











10.5 ± 4.2 3.4 ± 1.8 14.2 ± 2.1 144.13 ±
21.3






AMI Subjects (29) 31.7 ± 5.2 15 ± 5.8 41.8 ± 6.5 186.3 ±
19.6






p Value# 0.0007*** <0.0001**** <0.0001**** 0.004** 0.0008*** 0.0009*** 0.008** 0.03* 0.008**
OBESE Control Subjects
(33)
26.9 ± 9.1 7.1 ± 4.4 15.95 ± 1.9 167.9 ±
25.8








51.5 ± 12.4 31.35 ± 7.5 46.8 ± 5.9 219.4 ±
21.4






p Value# 0.02* <0.0001**** <0.0001**** 0.003** 0.18 0.95 0.03* 0.52 0.03*
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
Nalini et al. Thrombosis Journal  (2015) 13:12 Page 3 of 7ESPT method [21], cholesterol using CHOD-POD method
[22], HDL-cholesterol using glycerol-3-phosphate oxi-
dase – peroxidase-N-ethyl-methylanilin propan-sulphonate
sodic method using auto analyzer (BAYER RA 50; Bayer
Company India, Guindy, Chennai, India).ELISA method
Serum leptin (Diagnostics Biochem Canada Inc. Canada),
insulin (Cal biotech, California) and TNF-α (Orgenium
Laboratories Business Unit, Finland) were measured using
Sandwich ELISA technique according to the manufac-
turer’s instructions.Statistical analysis
Data obtained are presented as mean ± SD. As the data
obtained was not normally distributed, Mann–Whitney U
test was used to assess the difference in values between
AMI and control subjects. The relationship between con-
tinuous variables was evaluated using Spearman’s rank
correlation technique. The role of leptin on the incidence
of CVD was evaluated by analyzing its influence over
established cardiovascular risk factors such as insulin,
TNF-α and triglycerides using Multivariate Analysis of
Variance (MANOVA). A value of p < 0.05 is considered












BMI 0.57**** 0.54**** 0.32** 0.39**** 0.24*
*p<0.05; **p<0.01;****p<0.0001.Results
Table 1 shows the list of values of BMI, serum leptin, insu-
lin, TNF-α, glucose and triglycerides in AMI and control
subjects. In the present study, values of serum leptin are
found to be two to three fold higher in AMI subjects when
compared to that of control (non-CVD) subjects. Also, a
strong positive correlation is observed between serum lep-
tin and BMI in both AMI (r = 0.57, p < 0.0001; Table 2)
and control subjects (r = 0.54, p < 0.0001). Interestingly, a
significant difference (p < 0.0001) in serum leptin levels
was observed between men (22.3 ± 6.2 ng/ml) and women
(37.4 ± 7.3 ng/ml) in case of AMI group. However, no such
difference was observed between men (16.1 ± 5.3 ng/ml)
and women (15.0 ± 5.2 ng/ml) of control group.
Serum insulin levels (Table 1) are found to be highly ele-
vated in AMI subjects when compared to that of control
subjects. A notable finding is that serum insulin levels are
within the normal range in control whereas in AMI sub-
jects, its level is significantly higher. Serum insulin is found
to exhibit a good positive correlation with BMI (Table 2) in
both AMI (r = 0.32, p = 0.001) and control subjects (r =
0.39, p < 0.0001). Table 3 shows that there is also a positive
correlation between serum insulin and leptin in both AMI
(r = 0.27, p = 0.006) and control subjects (r = 0.22, p = 0.03).
Serum TNF-α level was measured in AMI subjects and












0.13 0.24* 0.12 0.5**** 0.2*
Table 3 Correlation of serum insulin, TNF-α and triglycerides with leptin in AMI and control subjects
INSULIN TNF-α TRIGLYCERIDES
AMI Subjects Control subjects AMI Subjects Control subjects AMI Subjects Control subjects
LEPTIN 0.27** 0.22* 0.27** 0.15 0.24* 0.03
*p<0.05; **p<0.01.
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three fold higher in AMI when compared to control
subjects. Tables 2, 3 and 4 show that serum TNF-α ex-
hibits a direct correlation with BMI (r = 0.24, p = 0.02),
leptin (r = 0.27, p = 0.007) and insulin (r = 0.21, p = 0.03)
respectively in AMI subjects but such a correlation was
not observed in case of control subjects.
Insulin, TNF-α and triglycerides are implicated in the
pathophysiological processes of CVD. To elucidate the
possible mechanism by which leptin promotes the onset
of AMI, its influence over the secretion of insulin, TNF-
α and triglycerides were analyzed using MANOVA in
AMI subjects and control subjects. MANOVA revealed a
significant main effect for leptin, (Wilks λ = 0.931, F (3,
200.00) = 4.975, p = 0.002, partial eta squared = 0.069) in
AMI subjects. Power to detect the effect was 0.910.
Given the significance of the overall test, the univariate
main effects of leptin were examined. Significant uni-
variate main effects for leptin was obtained for insulin
(F = 9.8, p = 0.002, partial eta square = 0.046, power = 0.876)
and TNF-α (F = 3.92, p =0.05, partial eta square = 0.019,
power = 0.505) in AMI subjects. Thus, MANOVA ana-
lysis show that leptin influence the secretion of insulin
(p = 0.002) and TNF-α (p = 0.05) in AMI subjects.
Analysis of biochemical parameters has yielded some
interesting results. Serum glucose levels (Table 1) are
found to be higher in AMI when compared to that of
control subjects of different BMI. Overweight and obese
AMI subjects are also found to possess a higher value of
serum triglycerides when compared to control subjects.
However, there is no significant difference in serum tri-
glycerides between normal weight control and AMI sub-
jects. Also interestingly, a positive correlation is observed
between serum triglycerides and leptin in AMI subjects
(r = 0.24, p = 0.03) (Table 3) but not in control subjects.
Serum values of cholesterol, HDL and VLDL are found
to be higher in overweight AMI when compared to con-
trol subjects. Serum LDL level is found to be in normal
range in case of control subjects irrespective of their BMI
but its value is significantly higher in overweight AMI and
obese AMI subjects.Table 4 Correlation of TNF-α with insulin in AMI and
control subjects
TNF-α
AMI Subjects Control subjects
INSULIN 0.21* 0.24*
*p<0.05.Table 5 illustrates the values of systolic and diastolic
blood pressure in AMI and control subjects. Both sys-
tolic and diastolic blood pressure are found to be higher
in AMI subjects than in control subjects.
Waist to hip ratio was also measured and interestingly
it is found to exhibit a significant positive correlation
with triglycerides (r = 0.26, p = 0.009) and VLDL (r = 0.35,
p = 0.0001) only in the case AMI subjects. No such correl-
ation is observed in the case of control subjects (Table 6).Discussion
Obesity is a leading cause of preventable death, a grow-
ing epidemic and major contributor to CVD risk and
mortality in developed and developing nations [23]. It is
associated with a marked increase in circulating leptin
concentrations (Ob gene product) but the pathophysio-
logical mechanisms linking obesity and CVD are poorly
defined. Leptin receptors are expressed in atherosclerotic
lesions, and leptin signaling is implicated in the promotion
of both thrombosis and atherosclerosis in experimental
models, suggesting a role for leptin in the progression of
CVD [24]. In the present study, we analyzed the serum
levels of leptin and its influence over insulin, TNF-α and
triglycerides in CVD patients and control subjects in order
to understand the role played by leptin in the pathogenesis
of CVD.
Recent evidences indicate that under normal conditions
leptin may be an important factor in regulating energy bal-
ance [25], but during situations of hyperleptinemia, this
hormone may function pathophysiologically and might
lead to progression of CVD [26]. This may be mediated
through various atherogenic effects of leptin including its
effect on blood pressure [27], platelet aggregation [28], for-
mation of arterial thrombosis [29] and inflammatory vas-
cular response [30]. Also, high levels of leptin are believed
to be associated with lower arterial distensibility, an index
of circulatory function and are found to be involved in the
pathogenesis of atherosclerotic process [31]. In the present
study, serum leptin is found to be two to three fold higher
in AMI subjects when compared to control subjects in all
the categories of BMI (viz., normal weight, overweight
and obese). These findings suggest that individuals with
elevated leptin levels may have a greater risk for the in-
cidence of CVD. Also interestingly, serum leptin levels
were found to be significantly higher in women with
AMI than in men with AMI. The mechanism behind
this gender differences is not fully understood, but still,
Table 5 Values of systolic and diastolic blood pressure, waist to hip ratio in AMI and control subjects
BMI CLASS (Kg/m2) SYSTOLIC BP (mm Hg) DIASTOLIC BP (mm Hg) WAIST TO HIP RATIO
AMI subjects (100) 139.4 ± 25.7 93.3 ± 15.4 0.94 ± 0.06
Control subjects (100) 125.4 ± 20.04 85.8 ± 14.8 1.01 ± 0.09
P value# 0.0001*** 0.0003*** 0.0001***
****p<0.001.
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in this regard [32].
Leptin is also found to be positively correlated to BMI
in both AMI and control subjects. The observed elevation
in leptin levels during obese conditions suggests that they
are leptin resistant and hence, they possess a greater risk
for the incidence of CVD. Another interesting observation
is that serum leptin level is higher in normal weight AMI
subjects than in overweight control subjects. This promin-
ent rise in serum leptin levels suggest that metabolic
parameters other than obesity might influence leptin
secretion during pathological conditions thereby resulting
in leptin resistance.
CVD is demonstrated to be characterized by resistance
to insulin mediated glucose disposal. Insulin resistance
as well as compensatory hyperinsulinemia associated with
insulin resistance is shown to be independent predictors
for CVD [33]. In the present study, serum insulin values
are found to be higher in AMI subjects than in control
subjects. Interestingly, serum glucose is also found to be
high in them in spite of higher insulin levels. Thus, ele-
vated levels of glucose along with increase in insulin sug-
gest that metabolic conditions such as hyperinsulinemia
could be an added risk for the incidence of CVD. More-
over, serum insulin is found to exhibit a significant positive
correlation with BMI and leptin in both AMI and control
subjects thereby suggesting that hyperleptinemia might be
associated with the development of obesity and subse-
quent metabolic abnormalities such as hyperinsulinemia.
TNF-α is one of the most potent pro-inflammatory
cytokine that play a pathogenic role in chronic inflamma-
tory diseases [34]. It is reported to be involved in every
step of inflammation from initiation to downregulation
and each characteristic lesion of atherosclerosis [35]. In
the present study, serum TNF-α level is found to be
threefold higher AMI subjects than in control subjects.
It is also found to be positively correlated to leptin in
AMI subjects thereby suggesting that leptin might causeTable 6 Correlation of serum triglycerides and VLDL with wai
TRIGLYCERIDES
AMI Subjects Control
WAIST TO HIP RATIO 0.26** 0.02***
**p<0.01; ***p<0.001.an increase in TNF-α expression which in turn might
exert a pro-atherogenic role in CVD.
To elucidate the possible mechanism by which leptin
could promote the onset of CVD, its influence over the
secretion of insulin, TNF-α and triglycerides were analyzed
using MANOVA in CVD subjects and control subjects.
MANOVA analysis suggests that leptin might exert its
pro-atherogenic role by stimulating the secretion of TNF-α
and insulin. Our reports may be regarded as preliminary
data and an in-depth study both in vivo and in vitro will
enable us to broaden our vision over the pro-inflammatory
role of leptin during the pathogenesis of CVD.
In the present study, serum triglycerides are found to
be higher in AMI subjects than in control subjects. In
addition, serum leptin levels are found to be positively
correlated to serum triglycerides in AMI subjects. More-
over, serum cholesterol, HDL, LDL and VLDL are found
to be higher in overweight AMI subjects when compared
to that of control subjects. Higher VLDL triglyceride out-
put are reported to activate cholesteryl ester transfer pro-
tein, which in turn result in triglyceride enrichment of
LDL and HDL [36] and the small, dense LDL particles are
demonstrated to be more susceptible to oxidative modifi-
cation, [37,38]. In addition, waist to hip ratio is also found
to exhibit a significant positive correlation to triglycerides
and VLDL in AMI subjects but such a correlation is
not observed in control (non-CVD) subjects. All these
observations suggest that increased visceral obesity in
association with elevated serum levels of leptin, insulin,
TNF-α, triglycerides, and VLDL may act synergistically
to increase one’s risk of acquiring CVD.
Systolic and diastolic blood pressure are found to be
higher in AMI subjects than in control subjects. Evidences
suggest that uncontrolled and prolonged elevation of
blood pressure in AMI can lead to a variety of changes
in the myocardial structure, coronary vasculature, and con-
duction system of the heart (http://emedicine.medscape.
com/article/162449-overview). These changes in turn canst to hip ratio in AMI and control subjects
VLDL
subjects AMI Subjects Control subjects
0.35 0.01
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system diseases, and systolic and diastolic dysfunction of
the myocardium, complications that manifest clinically as
angina or myocardial infarction.
Taken together, in the present study, circulating levels
of leptin are found to be associated with well defined
cardiovascular risk factors such as obesity, triglycerides,
insulin and TNF-α in AMI subjects. Our results suggest
that leptin may act as a risk factor for CVD and might
mediate obesity and CVD by augmenting inflammatory
events. However, further studies focusing on the pro-
inflammatory role of leptin during the pathogenesis of
AMI will aid in the development of leptin based thera-
peutic strategies to combat CVD.
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